EcoDrugPlus

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSOCUG00000025638
Gene Symbol: CXCR2
2 Cross references
237 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSOCUG00000001923
Gene Symbol: CXCR4
2 Cross references
283 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSOCUG00000010733
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSOCUG00000008221
Gene Symbol: TOP1
3 Cross references
270 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSOCUG00000002814
Gene Symbol: TOP2A
2 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSOCUG00000000717
Gene Symbol: TOP2B
2 Cross references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSOCUG00000015526
Gene Symbol: EML4
3 Cross references
209 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSOCUG00000000786
Gene Symbol: EPHA2
2 Cross references
124 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSOCUG00000010465
Gene Symbol: EPHA3
3 Cross references
215 Possible Orthologues:

Eph Receptor B4

Ensembl ID : ENSOCUG00000016902
Gene Symbol: EPHB4
2 Cross references
166 Possible Orthologues:

Fxyd Domain Containing Ion Transport Regulator 2

Ensembl ID : ENSOCUG00000010359
Gene Symbol: FXYD2
2 Cross references
74 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSOCUG00000015784
Gene Symbol: FYN
3 Cross references
261 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).